AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6092982
Drug: HiNaAc dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiNaAc dialysis (high sodium acetate, Na = 144, acetate = 33 mEq/l)
Trial: 6092982
Drug: LoNaAc dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LoNaAc dialysis (sodium acetate, Na = 134, acetate = 33 mEq/l)
Trial: 29664328
Drug: Monthly family
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly family expenditure
Trial: 15625424
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula with 0.8 g/100 ml GOS/FOS (OSF group)
Trial: 9656585
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of iodised oil (Lipiodol®) administered orally in Namentenga
Trial: 9656585
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of iodised oil (Lipiodol®) administered IM in Passore
Trial: 7893024
Drug: Bupivacaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (1 mg/kg of 0.5% bupivacaine with epinephrine 1:200000 in 20 mL of saline 0.9%)
Trial: 7893024
Drug: Lidocaine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (3 mg/kg of 2% lidocaine with epinephrine in 20 mL of saline 0.9%)
Trial: 7893024
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL of saline 0.9%)
Trial: 2505216
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg tobramycin solution, inhaled 3 times daily (15 patients)
Trial: 2505216
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL saline, inhaled 3 times daily (12 patients)
Trial: 21810191
Drug: Niacin (up
RxNorm normalized name: NIACIN (UPSHER-SMITH) 250MG SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (up to 1,500 mg daily for 12 weeks)
Trial: 19472972
Drug: Sequential bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential bilateral TKA under 1 anesthetic
Trial: 11354235
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of sertraline
Trial: 9442548
Drug: Sulpiride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (200 mg/day)
Trial: 3107808
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) and Enteral Feeding Program
Trial: 29609566
Drug: Regular pulsatile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular pulsatile cupping with 8 treatments plus paracetamol on demand (n=37)
Trial: 29609566
Drug: Minimal cupping
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal cupping with 8 treatments plus paracetamol on demand (n=36)
Trial: 29609566
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with paracetamol on demand only (n=37)
Trial: 29609566
Drug: Paracetamol intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol intake
Trial: 26105516
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid jelly Inner Power(®) (IP) once daily for 21 days
Trial: 25532503
Drug: Lafutidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine (20 mg)
Trial: 10853456
Drug: New endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New endocrine agents for receptor-positive patients
Trial: 6383779
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before therapy)
Trial: 23234087
Drug: Active observation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active observation of dance therapy (30 min. live session)
Trial: 9919039
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Interclean, model ID2
Trial: 2210795
Drug: Preparation I
RxNorm normalized name: Wound Care Preparation Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation I (modified allergenic extract)
Trial: 2210795
Drug: Preparation II
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation II (standard semi-depot extract)
Trial: 31397126
Drug: Auricular-point pressure
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular-point pressure combined with personalized music therapy
Trial: 27893933
Drug: Cancer and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer and Treatment Distress (CTXD) measure before transplantation and at 100 days and 180 days after HCT
Trial: 17516149
Drug: Injectable insulin
RxNorm normalized name: insulin degludec Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable insulin
Trial: 17516149
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment burden
Trial: 15026583
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg leflunomide
Trial: 15026583
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg leflunomide
Trial: 31461581
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of twice‐daily 16.5% Manuka honey + 1.3 mg/mL methylglyoxal sinonasal rinses and concurrent 10 days of placebo tablets (MH)
Trial: 31461581
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of twice‐daily saline sinonasal rinses and concurrent 10 days of culture‐directed antibiotic therapy (CON)
Trial: 25599305
Drug: Intrathecal clonidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal clonidine, 100 μg
Trial: 14499421
Drug: Intrathecal adenosine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal adenosine, 2 mg
Trial: 25599305
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (clonidine and adenosine)
Trial: 16978994
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive treatment strategy based on risk stratification
Trial: 11003427
Drug: Injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection technique
Trial: 3002786
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg kg‐1 and atropine 0.2‐0.4 mg i.m.
Trial: 3002786
Drug: Papaveretum 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum 0.4 mg kg‐1 and hyoscine 0.008 mg kg‐1 i.m.
Trial: 26850709
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional insulin pump therapy)
Trial: 21865211
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment (monotherapy in AFFIRM)
Trial: 21865211
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment (in combination with interferon β‐1a in SENTINEL)
Trial: 21865211
Drug: Natalizumab treatment
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab treatment (both alone and in combination with IFNβ)
Trial: 20345732
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU, Nebido(®)), 1,000 mg injected on day 1, followed by injections after 6 weeks and 18 weeks
Trial: 11684917
Drug: Aspirin, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, beta blockers, and angiotensin-converting enzyme inhibitors
Trial: 11684917
Drug: Reperfusion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion therapy (thrombolysis and primary angioplasty)
Trial: 9930483
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (n = 15)
Trial: 9930483
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (n = 16)
Trial: 8040664
Drug: Gemcitabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine at a dose of 1,000 mg/m2
Trial: 8040664
Drug: Gemcitabine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine at a dose of 1,250 mg/m2
Trial: 3051874
Drug: Prostaglandin vaginal
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin vaginal suppositories (PGE2)
Trial: 28974069
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 µg)
Trial: 19170659
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant treatment (31 +/- 19 min)
Trial: 19170659
Drug: Late surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late surfactant treatment (202 +/- 80 min)
Trial: 15566454
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg elemental iron daily (n=55)
Trial: 15566454
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg elemental iron weekly (n=56)
Trial: 9283506
Drug: 65 mg
RxNorm normalized name: opium 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg of methadone
Trial: 9283506
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of buprenorphine
Trial: 9283506
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of buprenorphine
Trial: 9283506
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of buprenorphine and methadone
Trial: 24200186
Drug: Both NG
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both NG and oral feeding
Trial: 16689375
Drug: Beta-blocker carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker carvedilol (5 mg/day)
Trial: 16689375
Drug: Beta-blocker carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker carvedilol (20 mg/day)
Trial: 16689375
Drug: Beta-blocker carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-blocker carvedilol (under 2.5 mg/day)
Trial: 12459688
Drug: Phenylephrine 100
RxNorm normalized name: phenylephrine 100 mcg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 microg/ml
Trial: 12459688
Drug: Ephedrine 3
RxNorm normalized name: ephedrine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 3 mg/ml
Trial: 8306010
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment (1 or more cycles)
Trial: 8306010
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (awaiting IVF treatment)
Trial: 27842499
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of remifentanil (0.3‐μg/kg/min for 5 min followed by 0.1‐μg/kg/min)
Trial: 27842499
Drug: Two bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two bolus injections of remifentanil (first bolus of 0.4 μg/kg and second bolus of 0.6 μg/kg after 3 min) and 0.1 μg/kg/min remifentanil
Trial: 20386122
Drug: Treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment protocol (4RM parallel back half-squat)
Trial: 16641287
Drug: Intranasal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 with biovector
Trial: 16641287
Drug: Intranasal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 without biovector
Trial: 16641287
Drug: Intramuscular vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccine with 15 microg hemagglutinin and MF59 adjuvant
Trial: 16641287
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (saline solution)
Trial: 8667183
Drug: Fentanyl (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.125 mg/70 kg i.v.)
Trial: 8667183
Drug: Fentanyl (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.25 mg/70 kg i.v.)
Trial: 8667183
Drug: Alfentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (1 mg/70 kg i.v.)
Trial: 8667183
Drug: Alfentanil (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (2 mg/70 kg i.v.)
Trial: 8667183
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg/70 kg i.m.)
Trial: 30726224
Drug: Single-dose sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sulfadoxine-pyrimethamine (SP) and 3 doses of amodiaquine (AQ) every three months
Trial: 29024410
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (OD) for 8 weeks
Trial: 29024410
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg OD for 8 weeks
Trial: 26743775
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg glucagon
Trial: 26743775
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg glucagon
Trial: 26743775
Drug: 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg glucagon
Trial: 22974886
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (3 mg/kg/d; group A)
Trial: 22974886
Drug: Fluconazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (800 mg loading dose and thereafter 400 mg/d; group B)
Trial: 20102150
Drug: RWJ-671818 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-671818 at 30 mg/kg
Trial: 20102150
Drug: RWJ-671818 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-671818 at 50 mg/kg
Trial: 20102150
Drug: RWJ-671818 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-671818 at 0.1 mg/kg, i.v.
Trial: 20102150
Drug: RWJ-671818 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWJ-671818 at 1.0 mg/kg, i.v.
Trial: 16935912
Drug: Abatacept 2
RxNorm normalized name: abatacept 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 2 mg/kg during double-blind phase
Trial: 16935912
Drug: Abatacept 10
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept 10 mg/kg during LTE
Trial: 8714425
Drug: Yohimbine 15
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 15 mg daily for 7 weeks
Trial: 8714425
Drug: Yohimbine 15
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 15 mg daily
Trial: 6336944
Drug: Retinoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinoid therapy
Trial: 31517964
Drug: Prize-linked savings
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prize-linked savings accounts with 1000 Kenya shillings (US 10) and weekly lottery-based rewards contingent on growth in savings balance
Trial: 24680227
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT), 16-20 sessions over 12-14 weeks
Trial: 17888019
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement in extraction sockets exhibiting periapical pathology (test group)
Trial: 17888019
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement in extraction sockets without periapical pathology (control group)
Trial: 15130377
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) alone, Group A
Trial: 15130377
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) and rosiglitazone in combination, Group C
Trial: 7962674
Drug: Ketorolac 15
RxNorm normalized name: ketorolac 15.75 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 15 mg
Trial: 29300259
Drug: Pharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic therapy for urgency-predominant urinary incontinence
Trial: 29300259
Drug: Sleeping medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleeping medications (used by 13% of participants 3 or more times per week)
Trial: 27017403
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current stimulation (IFCS) applied to submandibular and sublingual glands.
Trial: 23685640
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (n = 215), 0.5 mEq/kg/hr for the first hour and then 0.2 mmol/kg/hr for 23 hours
Trial: 23685640
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride infusion (n = 212)
Trial: 16365063
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g ALA/d from flaxseed oil capsules
Trial: 16365063
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil placebo capsules
Trial: 11038148
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Iloprost (50-100 microgram twice a day)
Trial: 11038148
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Iloprost (150-200 microgram twice a day)
Trial: 1358139
Drug: Classical antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical antihistamines
Trial: 23643848
Drug: Pumice treatment
RxNorm normalized name: Pumice
DrugBank: Pumice (DB14374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumice treatment
Trial: 16638294
Drug: Sequential MV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MV group (n = 47)
Trial: 1673977
Drug: Terfenadine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 180 mg orally
Trial: 1673977
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (IB) 0.5 mg nebulized aerosol
Trial: 1673977
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Terfenadine and Ipratropium bromide
Trial: 6460207
Drug: Zimelidine (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (100, 200 or 300 mg, p.o.)
Trial: 6460207
Drug: Zimelidine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine and alcohol combination
Trial: 26883950
Drug: 40 International
RxNorm normalized name: CONDOM,INTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 International Units oxytocin once daily
Trial: 25764160
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with pegylated IFN‐α (subcutaneously weekly)
Trial: 23846820
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low‐dose spironolactone (50 mg/d) and metformin (1000 mg/d)